Steven Goldstein is based in London and responsible for MarketWatch's coverage of financial markets in Europe, with a particular focus on global macro and commodities. Previously, he was Washington bureau chief, directing MarketWatch's economic, political and regulatory coverage. Follow Steve on Twitter: @MKTWgoldstein.
The trial success of Novo Nordisk’s hit drug against kidney failure sent shares of a German kidney dialysis services firm plummeting on Wednesday.
Fresenius Medical Care shares XE:FME FMS slumped 23%, and shares of its part owner Fresenius XE:FRE lost 12%, after Novo Nordisk halted a trial of semaglutide versus placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease early because of its efficacy.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Should Walmart be data-mining your Ozempic prescriptions?Walmart says it’s using customer data to see if people who fill Wegovy or Ozempic prescriptions are buying less food, raising privacy questions.
Read more »
Food Stocks Are Falling. Don't Blame Ozempic.Packaged-food stocks are in the red as of late, and it may indicate that consumers are shifting to fresh produce, meat, deli, and bakery products.
Read more »
FDA Adds Warning To Ozempic Label About Ileus, Intestinal BlockageI am a writer, journalist, professor, systems modeler, computational, AI, and digital health expert, medical doctor, avocado-eater, and entrepreneur, not always in that order. Currently, I am a Professor of Health Policy and Management at the City University of New York (CUNY) School of Public Health, Executive Director of PHICOR (PHICORteam) and Center for Advanced Technology and Communication in Health (CATCH), and founder and CEO of Symsilico. My previous positions include serving as Profess
Read more »
Oprah Winfrey walks back criticism of Ozempic users after WeightWatchers touts drugWinfrey’s comments last month led to WeightWatchers stock nosediving by as much as 15% the next day.
Read more »
Food, clothing, airlines: Ozempic is coming for these industries and moreAs drugs that suppress appetite become more popular, investors and executives are examining how they might impact businesses from retailers to airlines.
Read more »
Walmart Spies on Ozempic Patients' Shopping Habits, Finds They're Buying Less FoodScience and Technology News and Videos
Read more »